Table 2. Baseline characteristics of the 7 included studies.
| Studies | Nations | Diseases | No. of Patients (male)and Control | Mean Age (years) | BMI (kg/m2) | Cell Types | Cell Dose*Times | Delivery Methods | Follow-up Period | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| Bhansali et al. 2017 [21] | India | T2DM | 10(8);10(6) | 48.2;51.9 | 28.7;26.4 | BM-MSCs | 1×106/kg*1 | SPD artery Splenic artery | 12m | ①②③ |
| Carlsson et al. 2015 [12] | Sweden | T1DM | 9(8);9(5) | 24;27 | 23.3;22.5 | BM-MSCs | 2.75×106/kg*1 | IV | 12m | ②③ |
| Chen et al. 2016 [22] | China | T2DM | 6(6);6(0) | 57.5;57.5 | 23.35;13.63 | UC-MSCs | 1×106/kg*4 | Pancreatic artery +IV | 24w | ①② |
| Hu et al. 2013 [23] | China | T1DM | 15(9);14(8) | 17.6;18.2 | 20.9;21.3 | UC-MSCs | 2.6×107*2 | IV | 24m | ② |
| Hu et al. 2016 [24] | China | T2DM | 31(17);30(16) | 52.43;53.21 | 26.74;27.03 | UC-MSCs | 1×106/kg*2 | IV | 36m | ①② |
| Zhang et al. 2016 [25] | China | T2DM | 16(9);17(7) | 22.1;21.6 | 20.8;21.1 | A-MSCs | 1×107/kg*1 | IV | 24m | ①②③ |
| Zhou et al. 2013 [26] | China | T2DM | 120(60);120(61) | 57.4;57.6 | Unknown | BM-MSCs | 1×107/kg*3 | Unknown | 3w | ①②③ |
Abbreviations: T1DM: type 1 diabetes mellitus, T2DM: type 1 diabetes mellitus, MBI: body mass index, BM-MSCs: bone marrow-mesenchymal stem cells, UC-MSCs: umbilical cord-mesenchymal stem cells, A-MSCs: amniotic-mesenchymal stem cells, SPD: superior pancreaticoduodenal artery, IV: intravenous. Outcomes: ①FPG, ②HbA1c, ③Fasting C-Peptide.